Answer · Testosterone Therapy

Does TRT cause prostate cancer?

Short answer

Current evidence does not show that TRT causes prostate cancer in carefully screened men. The saturation model explains why prostate tissue reacts strongly to testosterone only at very low levels. In the TRAVERSE trial, high-grade prostate cancer was rare and similar on testosterone or placebo. PSA usually rises a little in the first year, and a confirmed rise of more than 1.4 ng/mL within 12 months prompts urology review.

By the Ultimate Male team · Updated October 8, 2026

Stethoscope resting on a medical chart

Where did the worry come from?

The worry comes from a real observation: lowering testosterone to castrate levels slows advanced prostate cancer. For decades that led to a simple assumption that adding testosterone must speed cancer up. The saturation model paper in European Urology set out why that assumption does not hold in men who are not castrated: the dramatic effect of removing testosterone does not mean extra testosterone has a matching effect in the other direction.

What is the saturation model?

The saturation model says prostate tissue is highly sensitive to changes in androgen levels only at very low concentrations. Androgens act through the androgen receptor, and the receptor becomes fully occupied at testosterone levels well below the normal range. Past that point, extra testosterone has little further effect on prostate growth.

Think of a sponge that is already soaked: pouring more water on it does not make it heavier. Moving a man from castrate levels into the low range is a big change for the prostate; moving him from low into the normal range is a much smaller one. It is a model, not proof of safety, which is why trial data and monitoring still matter.

What does the trial evidence show?

The largest randomized evidence is reassuring. A TRAVERSE prostate analysis followed 5,204 men aged 45 to 80 with low testosterone for an average of about 22 months of treatment. Men with a PSA above 3.0 ng/mL or severe urinary symptoms were excluded.

  • High-grade prostate cancer: 5 of 2,596 men on testosterone (0.19%) versus 3 of 2,602 on placebo (0.12%), not a significant difference.
  • Any prostate cancer, urinary retention, prostate procedures and biopsies: no significant differences.
  • PSA: rose more on testosterone than on placebo.

The AUA guideline asks clinicians to tell patients there is no evidence linking testosterone therapy to the development of prostate cancer. The Endocrine Society’s 2026 statement adds an honest caveat: prostate cancer develops slowly, trials may not have followed men long enough, and long-term safety is not yet established.

What does PSA usually do in the first year?

PSA usually rises a little after starting TRT as the prostate responds to normal hormone levels again. A 2024 review in the Journal of Clinical Endocrinology and Metabolism notes that TRAVERSE saw a greater PSA increase on testosterone than placebo during the first year of treatment. A small bump is expected; a large or sustained one is not.

The Endocrine Society guideline sets the lines that call for a urologist:

Finding on TRT What happens
Small PSA rise in the first months Recheck on schedule
Confirmed rise of more than 1.4 ng/mL above baseline within 12 months Urology evaluation
Confirmed PSA above 4.0 ng/mL Urology evaluation
New abnormality on prostate exam Urology evaluation

“Confirmed” matters. A urinary infection, prostate inflammation and some medicines can push PSA up for reasons unrelated to cancer, as our page on what can raise PSA temporarily explains, so a high reading is repeated before decisions are made. Our page on a rising PSA on TRT walks through the follow-up.

Who needs more caution?

Some men need a closer look before and during treatment. Men with a PSA that is already elevated (see high PSA before TRT), a strong family history of prostate cancer, significant urinary symptoms, or a personal history of prostate cancer all fall outside the population TRAVERSE studied. For them, the plan is individual and often involves a urologist from the start.

How Ultimate Male watches the prostate

At Ultimate Male, PSA is part of the TRT pre-screening panel, so every man starts with a baseline before the first dose. Follow-up PSA checks are drawn on site at San Gabriel or Downey and compared against that baseline, using the thresholds above rather than a single number in isolation.

When a result crosses a line, you are referred to a urologist rather than reassured and sent home. If you have been putting off testosterone therapy because of prostate worries, a free 10-minute call is a good place to ask how your own history would be handled.

questions

Related questions.

Does TRT cause prostate cancer?

Still unsure? Take the free assessment

Can I start TRT if my father had prostate cancer?
Often yes, but with a more careful baseline and closer PSA follow-up. Family history raises your own risk, so it changes how the prostate is screened and monitored.
Does TRT make an enlarged prostate worse?
In TRAVERSE, urinary symptom scores changed no more on testosterone than on placebo, and urinary retention and prostate procedures were similar. Men with severe urinary symptoms were not enrolled, so they need individual review.
Can men treated for prostate cancer use TRT?
Sometimes, under specialist care. The AUA says the evidence is inadequate to quantify the risk-benefit ratio in men with a history of prostate cancer, so the decision is made case by case with a urologist.

This page is general education, not medical advice. A licensed clinician must review your symptoms, history and labs before any treatment decision. For chest pain, trouble breathing, signs of stroke or an erection lasting over four hours, call 911.

Ready when you are

Start with a free phone call.

Ten minutes. No pressure. We tell you honestly whether we can help.

Call 626-319-5261 Free assessment